Download PDF

1. Company Snapshot

1.a. Company Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.Iovance Biotherapeutics, Inc.


has collaborations and licensing agreements with H.Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG.The company was formerly known as Lion Biotechnologies, Inc.


and changed its name to Iovance Biotherapeutics, Inc.in June 2017.Iovance Biotherapeutics, Inc.


was incorporated in 2007 and is headquartered in San Carlos, California.

Show Full description

1.b. Last Insights on IOVA

Iovance Biotherapeutics' recent performance was driven by improved Q4 results, with $87M revenue and a 50% gross margin. The company's AMTAGVI therapy shows promise, with modeled $1.6B peak sales and expected first profit in 2028. A recent pilot clinical trial for TIL cell therapy in advanced soft-tissue sarcomas yielded positive early data, sparking investor interest. According to MarketBeat.com, the company has a consensus rating of "Hold" from 14 research firms. The company's cash runway extends into Q3 2027, with potential solutions including ex-U.S. partnerships.

1.c. Company Highlights

2. Iovance Biotherapeutics' 2025 Earnings: A Year of Robust Growth

Iovance Biotherapeutics delivered a strong financial performance in 2025, with total revenue reaching approximately $264 million, representing a 30% year-over-year growth. The company achieved a 50% margin from cost of sales in the fourth quarter, driven by the sales of Amtagvi and Proleukin. The actual EPS loss of $0.18 was narrower than the estimated loss of $0.22. The company's cash position was approximately $303 million at year-end, driven by commercial and clinical execution, operational efficiency, and financial discipline.

Publication Date: Mar -03

📋 Highlights
  • 2025 Revenue & Margin Growth:: Achieved 30% revenue growth to $264M and 50% cost of sales margin in Q4 2025.
  • Extended Cash Runway:: Cash position of $303M at year-end, extending runway to Q3 2027 via cost savings initiatives.
  • Lifileucel Market Potential:: TIL platform targeting NSCLC, a $7x larger market than advanced melanoma (~$1B peak sales potential).
  • High Response Rates in Sarcoma:: Lifileucel demonstrated 50% confirmed response rate in aggressive soft tissue sarcomas.
  • Manufacturing Efficiency:: Transitioned lifileucel production to own facility, achieving highest commercial success rate and improved gross margins.

Operational Highlights

The company's operational strength was evident in its ability to extend the cash runway into the third quarter of 2027, thanks to ongoing cost savings initiatives. Iovance's TIL platform has shown massive expansion potential, with lifileucel demonstrating best-in-class clinical response rates and durability in the registrational patient population. The company is rapidly advancing towards a supplemental biologics license application, with a potential accelerated approval and launch in the second half of 2027.

Pipeline Advancements

Iovance's robust pipeline is expected to drive future growth, with the lead indication for lifileucel in previously treated nonsquamous non-small cell lung cancer, a market approximately 7x larger than the PQS sales opportunity in advanced melanoma. The company is also exploring new indications, including previously treated patients with two aggressive soft tissue sarcomas, which demonstrated an unprecedented 50% confirmed response rate.

Valuation and Growth Prospects

Analysts estimate next year's revenue growth at 48.0%. The current valuation metrics, including a P/S Ratio of 4.77 and an EV/EBITDA of -3.16, suggest that the market is pricing in significant growth expectations. With a strong pipeline and operational excellence, Iovance Biotherapeutics is well-positioned to drive towards profitability through cost optimization initiatives.

Guidance and Outlook

The company plans to provide more detail on the US launch growth when they introduce full year revenue guidance in the near future. As Daniel Kirby noted, Amtagvi has a $1 billion peak sales opportunity in melanoma, with non-small cell lung cancer and sarcoma also contributing to the overall potential. With a strong foundation in place, Iovance Biotherapeutics is poised for continued growth and success in 2026 and beyond.

3. NewsRoom

Card image cap

Iovance Biotherapeutics to Present at Upcoming Conferences

Feb -26

Source: globenewswire.com

Card image cap

Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why

Feb -25

Source: 247wallst.com

Card image cap

IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress

Feb -25

Source: zacks.com

Card image cap

Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)

Feb -24

Source: seekingalpha.com

Card image cap

Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy

Feb -24

Source: benzinga.com

Card image cap

Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript

Feb -24

Source: seekingalpha.com

Card image cap

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates

Feb -24

Source: zacks.com

Card image cap

IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?

Feb -24

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.53%)

6. Segments

Autologous Tumor Infiltrating Lymphocytes

Expected Growth: 11.53%

Iovance Biotherapeutics' Autologous Tumor Infiltrating Lymphocytes' 11.53% growth is driven by increasing adoption in metastatic melanoma treatment, strong clinical trial results, and expanding research in solid tumors. Additionally, growing demand for personalized cancer therapies and strategic partnerships contribute to the segment's growth.

7. Detailed Products

Tumor Infiltrating Lymphocytes (TIL)

TIL is a type of adoptive cell therapy that utilizes a patient's own immune cells to target and attack cancer cells.

LN-145

LN-145 is an autologous adoptive cell therapy that utilizes TIL to target and attack cancer cells.

LN-144

LN-144 is an autologous adoptive cell therapy that utilizes TIL to target and attack cancer cells.

IOV-COM-101

IOV-COM-101 is a personalized neoantigen-directed T cell therapy that targets specific cancer mutations.

8. Iovance Biotherapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Iovance Biotherapeutics, Inc. has a unique product pipeline, and there are limited substitutes available in the market, reducing the threat of substitutes.

Bargaining Power Of Customers

Iovance Biotherapeutics, Inc. has a diverse customer base, and customers have some bargaining power due to the availability of alternative treatments, but the company's unique products and services mitigate this power.

Bargaining Power Of Suppliers

Iovance Biotherapeutics, Inc. has a diversified supplier base, and suppliers have limited bargaining power due to the company's strong negotiating position and the availability of alternative suppliers.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily enter the market, posing a significant threat to Iovance Biotherapeutics, Inc.'s market share and revenue.

Intensity Of Rivalry

The biotechnology industry is highly competitive, and Iovance Biotherapeutics, Inc. faces intense rivalry from established companies and new entrants, leading to a high level of competition.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 1.48%
Debt Cost 3.95%
Equity Weight 98.52%
Equity Cost 7.21%
WACC 7.16%
Leverage 1.50%

11. Quality Control: Iovance Biotherapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Revolution Medicines

A-Score: 4.3/10

Value: 6.2

Growth: 1.8

Quality: 4.5

Yield: 0.0

Momentum: 9.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Ionis Pharmaceuticals

A-Score: 4.2/10

Value: 6.0

Growth: 1.1

Quality: 4.4

Yield: 0.0

Momentum: 10.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Amicus Therapeutics

A-Score: 3.6/10

Value: 0.4

Growth: 7.4

Quality: 4.6

Yield: 0.0

Momentum: 5.5

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Denali Therapeutics

A-Score: 3.3/10

Value: 6.7

Growth: 3.7

Quality: 4.5

Yield: 0.0

Momentum: 2.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Janux Therapeutics

A-Score: 3.3/10

Value: 7.8

Growth: 3.4

Quality: 4.1

Yield: 0.0

Momentum: 3.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Iovance Bio

A-Score: 3.1/10

Value: 7.9

Growth: 5.7

Quality: 4.0

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

4.1$

Current Price

4.11$

Potential

-0.00%

Expected Cash-Flows